Background/Objectives: Academically sponsored cancer clinical trials (ACCTs) are essential for advancing patient-centered care, particularly in areas underserved by commercial research. The Canadian Cancer Clinical Trials Network (3CTN) was established to support high-quality multi-center ACCTs through coordinated infrastructure and funding. Over ten years, funders provided an average of CAD 4.3 million annually (~CAD 0.11 per capita), primarily from federal and provincial sources. This study evaluates the outcomes and impact of trials supported by 3CTN between 2015 and 2024. Methods: We conducted a descriptive analysis of 350 ACCTs that stopped recruiting and had primary completion dates within the study period. Trial characteristics, results, publication rates, and incorporation into clinical guidelines were assessed using registry data, peer-reviewed publications, and structured searches of oncology guidelines. Results: Among these 350 closed trials, 116 were Phase III studies. Of these, 36% were incorporated into clinical practice guidelines, and 7% were likely to be incorporated. Overall, 81% of trials were published in journals, and 45% posted results in public registries. Trials addressed diverse cancer types, with notable contributions in rare cancers and vulnerable populations. Conclusions: 3CTN-supported ACCTs had high completion and reporting rates, with substantial influence on clinical practice. These findings highlight how sustained infrastructure and modest public investment can deliver meaningful improvements in cancer care and inform evidence-based policy.
背景/目的：学术机构发起的癌症临床试验对于推进以患者为中心的医疗至关重要，尤其在商业研究覆盖不足的领域。加拿大癌症临床试验网络通过协调基础设施与资金支持，旨在推动高质量的多中心学术临床试验。过去十年间，资助方年均投入约430万加元（人均约0.11加元），资金主要来源于联邦及省级财政。本研究评估了2015年至2024年间该网络支持试验的成果与影响。 方法：我们对350项已结束招募且主要完成日期在研究周期内的学术临床试验进行描述性分析。通过注册数据、同行评审出版物及肿瘤学指南结构化检索，评估试验特征、结果、发表率及临床指南采纳情况。 结果：在350项已结束的试验中，116项为III期研究。其中36%已被纳入临床实践指南，7%有望被纳入。总体而言，81%的试验在期刊发表，45%在公共注册平台公布结果。这些试验涵盖多种癌症类型，在罕见癌症及脆弱人群研究中贡献显著。 结论：加拿大癌症临床试验网络支持的学术临床试验具有较高的完成率与成果报告率，对临床实践产生实质性影响。这些发现表明，持续的基础设施建设与适度的公共投入能够有效推动癌症诊疗水平提升，并为循证决策提供重要参考。
肿瘤(癌症)患者之家